Advancing a Winning Front in the War Against Cancer

Provectus Biopharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. Our product pipeline includes:

• PV-10 For Cutaneous, Recurrent, and Metastatic Melanoma
  • A Phase 2 clinical trial has been successfully completed, and preparations are underway for a Breakthrough Therapy Designation (BTD). Paths for expedited approval for PV-10 to treat cutaneous melanoma in the USA and abroad are being evaluated.
  • PV-10 has received Orphan Drug Designation from the US FDA for the treatment of metastatic melanoma.
• PV-10 For locally Metastatic Liver Cancer
  • An expanded Phase 1 clinical trial is currently underway.
  • PV-10 has received Orphan Drug Designation from the US FDA for the treatment of liver cancer.
• PV-10 For Recurrent Breast Cancer
  • A Phase 1 clinical trial has been successfully completed.
• A Compassionate Use Program for PV-10 is being conducted as an expanded access study.
• The Moffitt Cancer Center is performing a mechanism of action study to examine the systemic immune response induced by intralesional PV-10 injections.

Provectus' product pipeline also includes advanced therapies being developed to treat severe psoriasis and atopic dermatitis.

• PH-10 For Psoriasis
  • A Phase 2c randomized clinical trial has been successfully completed.
  • A Phase 2 clinical trial has been successfully completed.
• PH-10 For Atopic Dermatitis
  • A Phase 2 clinical trial has been successfully completed.
• PH-10's mechanism of action is currently being examined.

Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov.
Additionally, Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.